Replimune’s second product candidate to enter the clinic is an Immulytic™ that expresses an anti-CTLA-4 antibody-like protein WOBURN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) — Replimune Group Inc. (REPL), a biotechnology company developing oncolytic immuno-gene...
MCY-M11 is being evaluated in relapsed/refractory ovarian cancer and peritoneal mesothelioma CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential GAITHERSBURG, Md., Oct. 24,...
WALTHAM, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (AMAG) today announced that the results of PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) were published online in the American Journal of Perinatology. PROLONG was a...
Founder Mike Wenger to Join Staff as Vice President of Patient Engagement JERSEY CITY, NJ, US – Oct 24, 2019 – TrialScope, the global leader in transparency and disclosure compliance solutions, has acquired Clinical Trial Connect, a platform used by...
If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpoint Highly statistically significant results for all secondary efficacy endpoints...
Email
Text